1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication. On July 23, 2021, Imbrium Therapeutics exercised its option to license LYT-503/IMB-150 pursuant to which it is responsible for all future development activities and funding for LYT-503/IMB-150.

$3.8B²

Investments and Non-Dilutive Funding Raised by Founded Entities Since July 2018

Note: This figure represents the stage of development for each Founded Entity’s most advanced therapeutic candidate.PureTech retains control of  Entrega, Inc., and it is consolidated in PureTech’s financial statements. PureTech maintains ownership of equity interests, but does not control, Karuna Therapeutics, Inc., Akili, Inc., Sonde Health, Inc. Vor Biopharma Inc., and Vedanta Biosciences, Inc. Relevant ownership interests for non-public Founded Entities, Vedanta, Sonde and Entrega were calculated on a partially diluted basis (as opposed to a voting basis) as of June 30, 2023, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Karuna, Akili and Vor ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of October 31, 2023, August 3, 2023 and November 3, 2023, respectively. As of March 1, 2023, the date on which PureTech was deemed to no longer control Vedanta Biosciences, PureTech’s percentage ownership of Vedanta Biosciences was approximately 40.8%. Vedanta’s 2023 $106.5 million financing round was structured as convertible debt. PureTech’s current ownership does not take into account any potential future dilution, if applicable, as a result of conversion of that debt amount. With the exception of Plenity® and EndeavorRx®, candidates are investigational and have not been cleared by the FDA for use in the U.S.
² Funding figure can include private equity financings, loans and promissory notes, public offerings or grant awards, and gross proceeds from SPAC mergers. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations.
³ As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. PureTech retains its equity ownership in Karuna. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.

$350.5M

Consolidated Cash and cash equivalents as of June 30, 2023
Operational Runway into Q1 2026